about pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

PHA121 is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Data from Phase 1 studies in healthy volunteers demonstrate rapid exposure and predictable linear pharmacokinetics, and inhibition of bradykinin-induced hemodynamic changes in a human bradykinin-challenge study.  PHVS416, a softgel capsule formulation containing PHA121, is currently in Phase 2 clinical development for the on-demand treatment of HAE.

Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

management team

Berndt Modig

Berndt Modig

Chief Executive Officer, Director

Morgan Conn, Ph.D.

Morgan Conn, Ph.D.

Chief Business Officer

Annick Deschoolmeester

Annick Deschoolmeester

Chief Human Resources Officer

Jochen Knolle, Ph.D.

Jochen Knolle, Ph.D.

Chief Scientific Officer, Chief Operating Officer

Anne Lesage, Ph.D.

Anne Lesage, Ph.D.

Chief Early Development Officer

Peng Lu, M.D., Ph.D.

Peng Lu, M.D., Ph.D.

Chief Medical Officer

Joan Schmidt, J.D.

Joan Schmidt, J.D.

Chief Legal Officer

Wim Souverijns, Ph.D.

Wim Souverijns, Ph.D.

Chief Community Engagement & Commercial Officer

Anna Nijdam

Anna Nijdam

Head of Finance, Principal Accounting Officer

board of directors

David Meeker, M.D.

David Meeker, M.D.

Chair of the Board

Elisabeth Björk, M.D.

Elisabeth Björk, M.D.

Director

Anne Marie de Jonge Schuermans

Anne Marie de Jonge Schuermans

Director

Robert Glassman, M.D.

Robert Glassman, M.D.

Director

Berndt Modig

Berndt Modig

Chief Executive Officer, Director

Viviane Monges

Viviane Monges

Director, Audit Chair

Hans Schikan, Pharm.D.

Hans Schikan, Pharm.D.

Vice Chair of the Board

scientific advisors

Aleena Banerji, M.D.

Aleena Banerji, M.D.

Konrad Bork, M.D.

Konrad Bork, M.D.

Marcus Maurer, M.D.

Marcus Maurer, M.D.

Marc Riedl, M.D.

Marc Riedl, M.D.